AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27590442 — intervention group
Group type: EXPERIMENTAL
Intervention: Top quartile of satisfaction with access to medical care
Number of subjects: 23470
Study 25807891 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Syllable Transition (ReST) treatment
Number of subjects: 26
Study 25807891 — intervention group
Group type: COMPARATOR
Intervention: Nuffield Dyspraxia Programme‐Third Edition (NDP3)
Number of subjects: 26
Study 25807891 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ReST and NDP3
Number of subjects: 26
Study 23698063 — intervention group
Group type: COMPARATOR
Intervention: Continuous antiretroviral therapy (ART)
Number of subjects: 3280
Study 21372309 — intervention group
Group type: EXPERIMENTAL
Intervention: FES-induced cycling training
Number of subjects: 35
Study 21372309 — intervention group
Group type: COMPARATOR
Intervention: Placebo FES cycling
Number of subjects: 35
Study 18165562 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.085 microg x kg(‐1) x min(‐1)
Number of subjects: 70
Study 18165562 — intervention group
Group type: COMPARATOR
Intervention: N2O 66%
Number of subjects: 70
Study 16877621 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous consent process
Number of subjects: 30
Study 12538746 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine treatment for 24 weeks
Number of subjects: 0
Study 12538746 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 24 weeks
Number of subjects: 0
Study 11142481 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating regimen of bolus and continuous infusion 5-FU (200 mg/m2 continuous infusion) + weekly bolus 6-S-leucovorin (20 mg/m2)
Number of subjects: 214
Study 11142481 — intervention group
Group type: COMPARATOR
Intervention: Control arm: biweekly cycles of MTX (200 mg/m2 on day 1) followed by bolus 5-FU (600 mg/m2 on day 2) + 6-S-leucovorin rescue
Number of subjects: 214
Study 11142481 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm
Number of subjects: 214
Study 9095423 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily wound cleansing and dressing change
Number of subjects: 50
Study 9095423 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily dressing changes (Control)
Number of subjects: 50
Study 8242966 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine (mean optimal dose of 2.7 mg)
Number of subjects: 5
Study 8242966 — intervention group
Group type: EXPERIMENTAL
Intervention: Columbia rating scale and quantitative assessments (tapping, walking, pinboard)
Number of subjects: 5
Study 8242966 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone pretreatment
Number of subjects: 5
Study 8242966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 3728294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous procainamide
Number of subjects: 51
Study 3728294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous quinidine
Number of subjects: 51
Study 29397328 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE; 4 × 4 minutes; 85%-95% HRpeak; 24 sessions)
Number of subjects: 0
Study 29397328 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE; 24 sessions)
Number of subjects: 0
Study 29397328 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE-T; 16 sessions)
Number of subjects: 0
Study 29397328 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise (MICE; 50 minutes; 70% HRpeak; 24 sessions)
Number of subjects: 0
Study 26527417 — intervention group
Group type: EXPERIMENTAL
Intervention: A4250 3 mg/day
Number of subjects: 64
Study 26527417 — intervention group
Group type: EXPERIMENTAL
Intervention: A4250 1.5 mg twice daily
Number of subjects: 64
Study 26527417 — intervention group
Group type: COMPARATOR
Intervention: A4250 0.1, 0.3, 1, 3, or 10 mg (single administration)
Number of subjects: 64
Study 26527417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 24866613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 24
Study 24866613 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation
Number of subjects: 24
Study 21620515 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus pGlcNAc applied once
Number of subjects: 82
Study 21620515 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus pGlcNAc applied every other week
Number of subjects: 82
Study 21620515 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus pGlcNAc applied every 3 weeks
Number of subjects: 82
Study 21620515 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 82
Study 19669586 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 50
Study 19669586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19669586 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 19094432 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous remifentanil (0.3 - 0.6 microg/kg per min)
Number of subjects: 40
Study 19094432 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (5 - 10 microg/kg per h)
Number of subjects: 40
Study 15663590 — intervention group
Group type: EXPERIMENTAL
Intervention: Live lactobacilli in combination with low dose oestriol (Gynoflor)
Number of subjects: 360
Study 15663590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 12391951 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized guidelines
Number of subjects: 139
Study 12391951 — intervention group
Group type: COMPARATOR
Intervention: Paper-based guidelines
Number of subjects: 139
Study 10745532 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient strategy (n = 43)
Number of subjects: 262
Study 10745532 — intervention group
Group type: COMPARATOR
Intervention: In-patient strategy (n = 47)
Number of subjects: 262
Study 10745532 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction survey for all patients and family members
Number of subjects: 262
Study 7872940 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard instruction ('count all heartbeats you feel in your body')
Number of subjects: 112
Study 7872940 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure treatment in a subgroup of 40 patients
Number of subjects: 112
Study 2350208 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine
Number of subjects: 10
Study 2350208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2350208 — intervention group
Group type: COMPARATOR
Intervention: Controls (normal volunteers)
Number of subjects: 10
Study 247895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin plus tobramycin (TT)
Number of subjects: 82
Study 247895 — intervention group
Group type: COMPARATOR
Intervention: Carbenicillin plus gentamicin (CG)
Number of subjects: 82
Study 31478799 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Breast Tomosynthesis (DBT)
Number of subjects: 14848
Study 31478799 — intervention group
Group type: COMPARATOR
Intervention: Digital Mammography (DM)
Number of subjects: 14848
Study 31478799 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT
Number of subjects: 14848
Study 27777061 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% KNO3/3% O/MA dentifrice
Number of subjects: 139
Study 27777061 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% KNO3 dentifrice (active comparator)
Number of subjects: 139
Study 27777061 — intervention group
Group type: COMPARATOR
Intervention: 0% KNO3/3% O/MA dentifrice (placebo)
Number of subjects: 139
Study 27777061 — intervention group
Group type: COMPARATOR
Intervention: Regular fluoride dentifrice (negative control)
Number of subjects: 139
Study 24796714 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health educational program (90-min every 2 weeks for 3 months)
Number of subjects: 47
Study 24796714 — intervention group
Group type: COMPARATOR
Intervention: General information about oral health (control group)
Number of subjects: 47
Study 23866850 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial care during radiotherapy
Number of subjects: 178
Study 23866850 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only (Control)
Number of subjects: 178
Study 21640779 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine (YFV) and measles-mumps-rubella (MMR) vaccine given simultaneously
Number of subjects: 1769
Study 21640779 — intervention group
Group type: COMPARATOR
Intervention: Yellow fever vaccine (YFV) and measles-mumps-rubella (MMR) vaccine given 30 days apart
Number of subjects: 1769
Study 21640779 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine (YFV) and measles-mumps-rubella (MMR) vaccine
Number of subjects: 1769
Study 19120333 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose UVA1 phototherapy
Number of subjects: 28
Study 19120333 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband UVB phototherapy
Number of subjects: 28
Study 16829185 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (12 microg/kg followed by a continuous infusion of 0.1-0.2 microg/min)
Number of subjects: 22
Study 15054439 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g taurine daily for 8 weeks
Number of subjects: 20
Study 15054439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11096237 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 4222
Study 11096237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4222
Study 9068025 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified formula (MF)
Number of subjects: 12
Study 9068025 — intervention group
Group type: COMPARATOR
Intervention: Conventional formula (CF)
Number of subjects: 12
Study 9068025 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MF and CF
Number of subjects: 12
Study 8371204 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) interrupted 7 days before surgery (Group A)
Number of subjects: 64
Study 8371204 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) not discontinued (Group B)
Number of subjects: 64
Study 3520132 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil, 2.5 mg twice daily (n = 12)
Number of subjects: 23
Study 3520132 — intervention group
Group type: COMPARATOR
Intervention: Captopril, 25 mg twice daily (n = 11)
Number of subjects: 23
Study 3520132 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil after switch from captopril
Number of subjects: 23
Study 3520132 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril after switch from minoxidil
Number of subjects: 23
Study 3520132 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil vs Captopril
Number of subjects: 23
Study 31733985 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaler drug education
Number of subjects: 85
Study 31733985 — intervention group
Group type: COMPARATOR
Intervention: Control group (no inhaler drug education)
Number of subjects: 85
Study 31538602 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 206
Study 31538602 — intervention group
Group type: COMPARATOR
Intervention: No CPAP
Number of subjects: 206
Study 29782200 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive Sleep Apnea (OSA) group
Number of subjects: 46
Study 29782200 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 27454090 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin 40mg/day
Number of subjects: 30
Study 27454090 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/20mg/day
Number of subjects: 30
Study 27454090 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/40mg/day
Number of subjects: 30
Study 24170913 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal PEP breathing
Number of subjects: 20
Study 21749847 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine plus standard medical therapy
Number of subjects: 40
Study 21749847 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy alone
Number of subjects: 40
Study 20632084 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 250 mg/month (approved dose)
Number of subjects: 144
Study 20632084 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 250 mg plus loading dose (500 mg on day 0, 250 mg on days 14, 28, and monthly thereafter)
Number of subjects: 144
Study 20632084 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg (high dose)
Number of subjects: 144
Study 17156264 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized multimedia computer program for health education (n = 33)
Number of subjects: 65
Study 17156264 — intervention group
Group type: COMPARATOR
Intervention: Health education by a physician (n = 32)
Number of subjects: 65
Study 16192581 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 10 mg
Number of subjects: 151
Study 16192581 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 151
Study 16192581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 12474951 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavities prepared by Er:YAG laser irradiation
Number of subjects: 0
Study 12474951 — intervention group
Group type: COMPARATOR
Intervention: Cavities prepared by air-turbine
Number of subjects: 0
Study 10548902 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 3 x 120 mg/day
Number of subjects: 0
Study 10548902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8527701 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxatidine acetate 150 mg
Number of subjects: 84
Study 8527701 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg
Number of subjects: 84
Study 8527701 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxatidine acetate
Number of subjects: 84
Study 2337212 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 or 0.3 mg/kg diltiazem 60 seconds before laryngoscopy
Number of subjects: 20
Study 2337212 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 372027 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate
Number of subjects: 0
Study 372027 — intervention group
Group type: COMPARATOR
Intervention: Halcinonide
Number of subjects: 0
Study 31034561 — intervention group
Group type: EXPERIMENTAL
Intervention: Basivertebral nerve (BVN) radiofrequency ablation, n=27 (decreased opioid use)
Number of subjects: 69
Study 31034561 — intervention group
Group type: COMPARATOR
Intervention: Sham control, n=19 (decreased opioid use)
Number of subjects: 69
Study 30721963 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free mass
Number of subjects: 487404
Study 30721963 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass
Number of subjects: 487404
Study 30721963 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free mass (causal effect)
Number of subjects: 487404
Study 30721963 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass (causal effect)
Number of subjects: 487404
Study 30721963 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free mass (multivariate MR)
Number of subjects: 487404
Study 30721963 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass (multivariate MR)
Number of subjects: 487404
Study 28033561 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (10 days of intake)
Number of subjects: 48
Study 28033561 — intervention group
Group type: COMPARATOR
Intervention: Aspirin resistance tests (PFA‐200, VerifyNow®, TXB2)
Number of subjects: 48
Study 26273264 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX), amoxicillin (AMX) 500 mg, metronidazole (MET) 250 mg
Number of subjects: 31
Study 26273264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 24107737 — intervention group
Group type: EXPERIMENTAL
Intervention: LCI699 (aldosterone synthase inhibitor)
Number of subjects: 0
Study 24107737 — intervention group
Group type: EXPERIMENTAL
Intervention: LCI699
Number of subjects: 0
Study 21435642 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tramadol
Number of subjects: 120
Study 21435642 — intervention group
Group type: COMPARATOR
Intervention: Oral naproxen
Number of subjects: 120
Study 21435642 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration at fixed intervals
Number of subjects: 120
Study 21435642 — intervention group
Group type: COMPARATOR
Intervention: Pain scores
Number of subjects: 120
Study 19643125 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention with Coping Skills Training (CST) and health coaching
Number of subjects: 198
Study 19643125 — intervention group
Group type: COMPARATOR
Intervention: Educational intervention without CST and health coaching (Control)
Number of subjects: 198
Study 17825135 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol 800 microg
Number of subjects: 450
Study 17825135 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular oxytocin 10 IU
Number of subjects: 450
Study 15086765 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratinocyte monolayers on collagen pads (group 1)
Number of subjects: 15
Study 15086765 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratinocyte-microbeads (group 2)
Number of subjects: 15
Study 15086765 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple applications of keratinocyte-microbeads (group 3)
Number of subjects: 15
Study 15086765 — intervention group
Group type: COMPARATOR
Intervention: Comparison between group 1 and group 3
Number of subjects: 15
Study 11575533 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 20
Study 11575533 — intervention group
Group type: COMPARATOR
Intervention: 0.5% lidocaine
Number of subjects: 20
Study 9781859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerana inlays with a polyacid‐modified composite
Number of subjects: 60
Study 9781859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerana inlays with a highly viscous luting composite
Number of subjects: 60
Study 9781859 — intervention group
Group type: COMPARATOR
Intervention: Empress inlays with a highly viscous luting composite
Number of subjects: 60
Study 9781859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerana inlays with a low‐viscous luting composite
Number of subjects: 60
Study 7884018 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLU)
Number of subjects: 124
Study 7884018 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (IMI)
Number of subjects: 124
Study 7884018 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FLU and IMI
Number of subjects: 124
Study 6147866 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 0
Study 6147866 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam
Number of subjects: 0
Study 31183514 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab 840 mg intravenous plus trastuzumab and chemotherapy
Number of subjects: 374
Study 31183514 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and chemotherapy
Number of subjects: 374
Study 30285835 — intervention group
Group type: EXPERIMENTAL
Intervention: Care informed by results of an additional placental factor blood test
Number of subjects: 0
Study 30285835 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0
Study 26691769 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation (PRO group)
Number of subjects: 20
Study 26691769 — intervention group
Group type: COMPARATOR
Intervention: Control (CON group)
Number of subjects: 20
Study 22529036 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurobehavioral intervention (n = 25), weekly sessions
Number of subjects: 38
Study 22529036 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 13), standard weekly home visits
Number of subjects: 38
Study 23128439 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 128
Study 23128439 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 128
Study 20973982 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 300 μg Q2W or 500 μg Q3W (EDS)
Number of subjects: 752
Study 20973982 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa 150 μg QW (weekly)
Number of subjects: 752
Study 20973982 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (both groups)
Number of subjects: 752
Study 20973982 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa (QW group)
Number of subjects: 752
Study 17589695 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid material contact lens (DK 23)
Number of subjects: 22
Study 17589695 — intervention group
Group type: COMPARATOR
Intervention: Rigid-gas-permeable contact lens (DK 30)
Number of subjects: 22
Study 17589695 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lens types
Number of subjects: 22
Study 17362430 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically depressed patients
Number of subjects: 114
Study 17362430 — intervention group
Group type: COMPARATOR
Intervention: Normal matched subjects
Number of subjects: 114
Study 14702424 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump surgery
Number of subjects: 104
Study 14702424 — intervention group
Group type: COMPARATOR
Intervention: Off-pump surgery
Number of subjects: 104
Study 11049920 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 30
Study 11049920 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 30
Study 10323115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 40 mg intravenous injection at induction, followed by 20 mg tablet in the evening of the operation and 20 mg daily from days 2 to 7
Number of subjects: 35
Study 10323115 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium 75 mg intramuscular injection at induction, followed by 50 mg tablet 4 to 6 hours after operation and 50 mg three times daily for the next 6 days
Number of subjects: 35
Study 10323115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam group
Number of subjects: 35
Study 1728160 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 20
Study 1728160 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 20